You are here: Industry Insights > AbbVie

News List

AbbVie’s shares tank after cancer hopeful’s phase 2 setback pharmaphorum
March 26, 2018
AbbVie’s share price has nosedived after poor results from a phase 2 trial of its antibody-drug conjugate in advanced lung cancer.
AbbVie's shares fall nearly 12 percent after decision to scrap plan for accelerated FDA approval of Rova-T firstwordpharma
March 23, 2018
Shares in AbbVie fell nearly as much as 12 percent Thursday after the company said it will not seek accelerated FDA approval for the antibody-drug conjugate rovalpituzumab tesirine, also known as Rova-T
AbbVie, IMF collaborate to manage multiple myeloma biospectrumasia
March 23, 2018
Study will provide insight into the relatively unknown role of genetic mutations in response to treatment and the corresponding outcomes in patients with MM
Poor Mid-Stage Results Sink AbbVie’s Plans for Cancer Drug biospace
March 23, 2018
AbbVie announced that it will not ask for accelerated approval for Rova-T in third-line relapsed/refractory (R/R) small cell lung cancer (SCLC)
AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic biospace
March 22, 2018
AbbVie (NYSE: ABBV), today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage MM, the second most common blood cancer.1
AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elago biospace
March 14, 2018
AbbVie (NYSE:ABBV), announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.
AbbVie’s Elagolix Dazzles in Phase III Trial biospace
March 14, 2018
AbbVie and Neurocrine Biosciences, Inc. announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint.
Biogen and AbbVie Voluntarily Pull Multiple Sclerosis Drug Off the Market biospace
March 05, 2018
Biogen and AbbVie have voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short fiercepharma
February 09, 2018
Gilead Sciences' once-high-flying hepatitis C drugs have come a long way down since their peak sales years, but thanks to new competition from AbbVie, the company's important franchise will have another rough year in 2018.
AbbVie to Award Shareholders, Increase Employees' Pay on Rosy 2018 Forecast biospace
January 30, 2018
AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page